Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its second-quarter earnings report that exceeded analyst expectations. The medical technology company reported adjusted earnings per share of $0.67, surpassing the consensus estimate of $0.62, while sales reached $1.53 billion, beating the projected $1.49 billion.
The company's strong performance was driven by an 11.9% increase in sales, with notable growth in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. In light of these results, Edwards Lifesciences has raised its full-year total company sales growth guidance to 9% to 10%, projecting sales between $5.9 billion and $6.1 billion.
While the positive earnings report fueled the stock's after-hours rally, investors appeared to shrug off news of an FDA recall of Edwards Lifesciences' Arterial Cannula due to the risk of wire exposure. The company's robust financial performance and increased guidance seem to have overshadowed this regulatory concern, as the market responded enthusiastically to the overall strength of Edwards Lifesciences' business outlook.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。